开发了一种通过转铁蛋白修饰的多组分紫杉醇 (PTX) 负载 β-榄香烯纳米乳 (Tf-PE-MEs)，以增强非小细胞肺癌 (NSCLC) 的治疗。转铁蛋白修饰后，Tf-PE-MEs的粒径为（14.87±1.84）nm，zeta电位为（-10.19±0.870）mV。体外实验表明，Tf-PE-MEs可诱导A549细胞大量凋亡，表明其对A549细胞具有显着的细胞毒性。通过转铁蛋白修饰，Tf-PE-MEs 与 A549 细胞表面过表达的转铁蛋白受体 (TfR) 一起在肿瘤部位有效积累。这将增加靶细胞中 PTX 和 β-榄香烯的浓度，从而增强治疗效果。与单独使用 PTX 相比，Tf-PE-ME 在体内研究中表现出良好的抗肿瘤功效并降低了全身毒性。该研究具有良好的治疗潜力，为非小细胞肺癌的联合抗癌治疗提供了新策略。版权所有©2024。Elsevier B.V.出版。

A multi-component paclitaxel (PTX) -loaded β-elemene nanoemulsion by transferrin modification (Tf-PE-MEs) was developed to enhance non-small-cell lung cancer (NSCLC) treatment. After transferrin modification, the particle size of Tf-PE-MEs was (14.87 ± 1.84) nm, and the zeta potential was (-10.19 ± 0.870) mV, respectively. In vitro experiments showed that Tf-PE-MEs induced massive apoptosis in A549 cells, indicating that it had significant cytotoxicity to A549 cells. Through transferrin modification, Tf-PE-MEs accumulated at the tumor site efficiently with overexpressed transferrin receptor (TfR) on the surface of A549 cells. This will allow increasing PTX and β-elemene concentration in the target cells, enhancing the therapeutic effect. Compared to PTX alone, Tf-PE-MEs displayed good anti-tumor efficacy and diminished systemic toxicity in vivo studies. With favourable therapeutic potential, this study provides a new strategy for the combined anticancer treatment of non-small cell lung cancer.Copyright © 2024. Published by Elsevier B.V.